Combining Psychedelic-Assisted Therapy with Other Modalities — KAP+CBT, IFS, EMDR, Somatic Approaches

Psychedelic-assisted therapy (PAT) is rarely a stand-alone intervention. In every published controlled trial that has shown clinical signal — psilocybin for treatment-resistant depression, MDMA for PTSD, ketamine across depression and other indications — the medication is delivered inside a defined psychotherapy frame. The substance does pharmacological work; established psychotherapy modalities do the cognitive, emotional, somatic, and relational work that turns the substance's effects into change. This article is a Canadian guide to how psychedelic-assisted therapy combines with the principal evidence-based modalities — CBT and trauma-focused CBT, IFS, EMDR, somatic experiencing, ACT, mindfulness-based approaches, DBT, CPT, conjugal CBT, and group models like Roots to Thrive — and how ATMA CENA's three-phase pathway and coordinated care model accommodate them.

Key takeaways

• PAT is not a stand-alone intervention. Every credible protocol pairs the substance with a defined psychotherapy frame.
• Multiple modalities can host PAT. CBT, trauma-focused CBT (CBT-T), CPT, IFS, EMDR, somatic experiencing, sensorimotor psychotherapy, ACT, mindfulness-based approaches, DBT, and conjugal CBT are all used in current PAT practice and protocols.
• The trial protocols are explicit. Mitchell 2021/2023 MAPP1/MAPP2 used a CBT-grounded inner-directed therapy frame; Goodwin 2022 COMP001 used a structured psychological-support frame; CPT and CBCT have published combination work with MDMA.
• No single modality is "best." Choice depends on indication, trauma history, the patient's existing therapist's primary modality, learning style, and substance.
• Substance matters. Ketamine (shorter integration windows) commonly pairs with CBT, ACT, and IFS; psilocybin (longer, autobiographical material) pairs with psychodynamic, IFS, and CBT-T; MDMA-AT pairs with trauma-focused frames including CPT and EMDR.
• ATMA CENA's three-phase model accommodates multiple primary modalities. Through coordinated care, the existing therapist's primary modality is preserved rather than replaced.
• No outcome promises. Adding psychedelic medicine to a psychotherapy frame does not predict response. The integrity of the primary therapeutic relationship matters more than which acronym is on the door.

Why combination — and why this is not optional

Psychedelic-assisted therapy is sometimes described in popular media as if the substance is the therapy. That is not how the evidence base is built. In every phase 2 and phase 3 trial that has driven the modern PAT literature, the medicine sits inside a structured psychotherapy frame — preparation sessions, supervised dosing with present clinicians, and a defined integration phase using established psychotherapeutic technique.

The mechanism case is straightforward: psychedelics increase neuroplasticity and access to material (autobiographical, emotional, somatic) that is otherwise harder to reach in standard psychotherapy. That openness is therapeutically useful only if there is a structured therapeutic process to work with what surfaces. Without that frame, openness is just openness — vivid, often meaningful in the moment, but unreliably converted into durable change.

This is why the question is rarely "PAT or my existing therapy?" The clinically coherent question is: which existing therapeutic frame best hosts psychedelic-assisted work for this patient, this indication, and this substance?

CBT and trauma-focused CBT with PAT

Cognitive Behavioural Therapy (CBT) is the most-evidenced psychotherapy in modern psychiatry, and it remains a natural host for psychedelic-assisted work — particularly for depression and anxiety indications.

• Standard CBT + PAT (depression, anxiety): cognitive restructuring during integration is a strong fit for material surfaced in dosing. A patient who, during a psilocybin or ketamine session, notices a pattern of self-criticism can take that observation into integration sessions and apply CBT's cognitive-restructuring technique to the underlying belief. Behavioural activation — a CBT staple for depression — fits PAT integration's "translation to behaviour" function unusually well.
• Trauma-focused CBT (CBT-T) + PAT (PTSD): CBT-T is the family of CBT protocols specifically designed for traumatic-stress material. The Mitchell 2021 MAPP1 (PMID 33972795) and Mitchell 2023 MAPP2 (PMID 37640273) MDMA-AT protocols built their inner-directed therapy frame on trauma-informed CBT principles, with explicit emphasis on the patient's own meaning-making rather than therapist interpretation.

For Canadian patients whose existing therapy is already CBT, the addition of psychedelic medicine is often the lowest-friction PAT pathway — the cognitive frame the patient already knows continues, with the medication-assisted sessions woven in.

IFS — Internal Family Systems

Internal Family Systems (IFS), developed by Richard Schwartz, has become one of the most-used integration frames in current psychedelic-assisted therapy practice. The fit is structural: IFS frames the psyche as a system of "parts" — protectors, exiles, the Self — and psychedelic experiences very frequently surface material that feels parts-shaped. Patients commonly report contact with younger or wounded aspects of themselves during psilocybin and MDMA sessions, and the IFS vocabulary maps cleanly onto that phenomenology.

IFS is used heavily in MDMA-AT integration in particular, where the connection to attachment-bound exile parts and the therapeutic stance of "Self-led" presence aligns with what MDMA pharmacologically supports. Many therapists trained in IFS find the addition of psychedelic medicine accelerates work that would otherwise take longer in standard talk therapy — though, as with every modality on this list, this is a clinical observation rather than an outcome guarantee.

EMDR — Eye Movement Desensitization and Reprocessing

EMDR (Shapiro), one of the principal trauma-processing modalities along with CPT and prolonged exposure, has growing combination work with psychedelic-assisted therapy. The pairing logic is mechanism-based: EMDR uses bilateral stimulation to support reprocessing of traumatic memory; PAT (especially MDMA-AT) reduces fear-network reactivity and supports re-engagement with traumatic material. Combining the two is being studied and is in clinical use among Canadian and US therapists with both certifications.

For Canadian patients whose existing trauma therapy is EMDR, coordinated care arrangements that preserve the EMDR therapist as primary while layering MDMA-AT or KAP for trauma indications are an emerging and clinically reasonable design. Combination EMDR + PAT is not a substitute for the standard MAPP-style protocol where MDMA-AT is the indicated treatment.

Somatic Experiencing and Sensorimotor Psychotherapy

Body-based modalities — Peter Levine's Somatic Experiencing and Pat Ogden's Sensorimotor Psychotherapy — pair naturally with psychedelic-assisted therapy because psychedelic experiences are themselves substantially somatic. Patients report bodily sensation, energetic patterns, and held tension as central content of dosing sessions, particularly with MDMA and high-dose psilocybin.

Somatic Experiencing's emphasis on titration, pendulation, and discharge of activation maps onto integration work where the patient is metabolizing somatic material from dosing. Sensorimotor Psychotherapy's three levels (sensorimotor, emotional, cognitive) provide a framework for moving between body-level processing and cognitive integration without forcing premature meaning-making. Bessel van der Kolk's work on body-based trauma treatment (and his role as senior author on MAPP2) is often cited in this combination literature.

ACT — Acceptance and Commitment Therapy

Acceptance and Commitment Therapy (Hayes), centred on psychological flexibility — defusion from difficult thoughts, acceptance of inner experience, values clarification, committed action — is increasingly framed as a strong theoretical match for psychedelic mechanism. Watts and Luoma (2020) made the case explicitly: the psychological flexibility model is one of the better-fitting psychotherapy frameworks for understanding what psychedelic experiences are doing therapeutically.

ACT is widely used in ketamine and Spravato integration, where the relatively short integration window suits ACT's structured, behaviour-change-oriented approach. For depression and anxiety indications, ACT + PAT is one of the cleaner fits in the modality landscape.

Mindfulness-based approaches — MBCT and MBSR

Mindfulness-based approaches — MBCT (Segal, Williams, Teasdale) for depression, MBSR (Kabat-Zinn) more broadly — function as both preparation-phase support and integration-phase support for PAT. The capacity to bring non-judgmental attention to inner experience is exactly the capacity that supports a productive dosing session and a productive integration phase.

Many Canadian clinics (ATMA CENA included) incorporate mindfulness elements into preparation: paced breathing, body scans, orienting techniques. For patients who already have a mindfulness practice or have completed an MBCT or MBSR course, that capacity transfers directly into the PAT process.

DBT — Dialectical Behavior Therapy

Dialectical Behavior Therapy (Linehan), developed for borderline personality disorder and emotion-dysregulation populations, brings something specific to the psychedelic-assisted therapy landscape: an established framework for distress tolerance. DBT skills modules — distress tolerance, emotion regulation, interpersonal effectiveness, mindfulness — are directly applicable when psychedelic experiences surface intense affect or when integration encounters dysregulating material.

For patients with significant emotion dysregulation or BPD-spectrum presentations, DBT-trained clinicians offer a coherent host frame for KAP work in particular. Eligibility for psilocybin and MDMA-AT in this population is more restrictive in protocol literature, and clinical decision-making is individualized.

CPT — Cognitive Processing Therapy for PTSD

Cognitive Processing Therapy (Resick), one of the principal evidence-based PTSD treatments, has an explicit place in MDMA-AT combination literature. The Mitchell 2021/2023 MAPP1/MAPP2 protocols' inner-directed therapy frame draws on CPT-style cognitive work around traumatic-event meaning, particularly in the integration sessions following each of the three dosing sessions. For trauma-focused presentations, CPT-trained clinicians find their existing technique transfers cleanly to MDMA-AT integration work.

CBCT — Cognitive-Behavioural Conjugal Therapy and couples MDMA

A specific and notable case: Anne Wagner and colleagues' work combining MDMA with Cognitive-Behavioural Conjugal Therapy for PTSD where one partner has the diagnosis. Published trial work (Wagner and colleagues) extended the MDMA-AT protocol into couples treatment, with both members of the couple present and the CBCT framework structuring the relational work. This is the leading published example of MDMA-AT combined with a couples-therapy modality and is one of the more interesting expansion points in the literature.

Group models — Roots to Thrive

The Roots to Thrive program in Nanaimo, BC, has published a group-based psilocybin and ketamine model that combines clinical PAT with a community-of-practice structure. Dames et al. 2025 in Frontiers in Psychiatry is the most-cited published outcome paper on the model. The approach is itself a combination — group integration as primary frame, with elements of mindfulness, ACT, and trauma-informed practice woven in. Group integration is not for every patient; for some, the group format is the host frame that makes the work possible.

For ATMA CENA's group ketamine work in the Canadian context, see Group Ketamine Therapy.

How substance choice interacts with modality choice

Substance pharmacology shapes which modalities tend to host the work most cleanly. The pairings below are clinical heuristics, not rules.

Ketamine and esketamine

• Integration window: shorter, interleaved with ongoing dosing course (Spravato twice-weekly induction; off-label IV/IM ketamine series).
• Common modality pairings: CBT, ACT, IFS (selected presentations).
• Why: ketamine sessions are shorter and less narrative than psilocybin or MDMA; the integration windows are more "translation-to-behaviour" focused than "deep autobiographical metabolization." Modalities that work well in shorter, structured sessions fit naturally.

For substance pathway: Ketamine Therapy in Canada.

Psilocybin

• Integration window: substantial; often weeks-long phase per dosing session.
• Common modality pairings: psychodynamic, IFS, CBT-T, with mindfulness-based and ACT-informed elements.
• Why: psilocybin produces longer (5–6 hour), more autobiographical, more meaning-laden experiences. The integration phase carries denser material, often calling for parts-based or psychodynamic work.

For substance pathway: Psilocybin Therapy in Canada.

MDMA-assisted therapy

• Integration window: three integration sessions per dosing session per Mitchell 2021/2023 MAPP1/MAPP2 — nine integration sessions total over the course.
• Common modality pairings: trauma-focused — CPT, EMDR, CBT-T, IFS, somatic experiencing, sensorimotor psychotherapy.
• Why: the indication is PTSD; trauma material is the central content; trauma-focused modalities are the natural hosts.

For substance pathway: MDMA-Assisted Therapy in Canada.

Choosing a modality — the clinical reality

There is no algorithm for matching modality to patient. The honest framing is that no single modality is best. Clinical decision-making typically considers:

• Existing care. If the patient already has a therapist they trust working in CBT, IFS, EMDR, somatic experiencing, or another evidence-based modality, that relationship is the strongest predictor of whatever long-term work follows. The PAT-specific work layers on top through coordinated care.
• Indication. Trauma indications call for trauma-focused frames (CPT, EMDR, CBT-T, somatic). Depression indications often suit CBT, ACT, IFS, or psychodynamic frames. Substance-use indications often suit motivational interviewing layered with one of the above plus group support.
• Trauma history. A patient with significant complex trauma needs a host modality with the technique to handle the material that may surface. Untrained mishandling of complex trauma material is a real harm.
• Learning style and modality preference. Some patients are reflexively suited to cognitive frames; others to somatic, parts-based, or relational frames. Patient preference is clinically relevant.
• Therapist availability and credentialing. In the Canadian landscape, therapist availability across modalities varies by province and city. The pragmatic reality is that the best-trained therapist available is often the right answer.

ATMA CENA's three-phase model and coordinated care

ATMA CENA's pathway is explicitly designed to accommodate multiple primary modalities rather than impose a single modality on every patient. Two design choices make this work:

• Three-phase structure (preparation + dosing + integration): the structure is modality-agnostic. Preparation can be done in a CBT, IFS, EMDR-aware, somatic, or ACT frame depending on the patient. Integration likewise.
• Coordinated care: where the patient already has an existing therapist, the existing therapist's primary modality is preserved. ATMA CENA layers psychedelic-specific work on top — preparation conversations, dosing supervision, and PAT-specific integration sessions — while the patient's primary therapeutic relationship continues. Material from dosing is brought back to the primary therapist for ongoing work in the modality and relationship the patient already has.

For pathway-phase detail: Preparation Phase of Psychedelic-Assisted Therapy and Integration Phase of Psychedelic-Assisted Therapy. For coordinated care: ATMA CENA's coordinated care model.

What the evidence does — and does not — show

• Combination is supported, not optional. Every credible PAT trial has been a combination trial. The evidence base for psychedelic-assisted therapy is, definitionally, an evidence base for combined-modality treatment.
• No head-to-head modality winner. There is no published evidence supporting one host modality over another across indications. The published trial frames (MAPP-style trauma-focused CBT/inner-directed; COMP001-style structured psychological support) are not claimed to be optimal — they are the frames the trials used.
• Therapeutic alliance with the primary therapist is a stronger predictor than modality acronym. This is a long-standing finding in psychotherapy outcome research and there is no reason to think PAT escapes it.
• No outcome promises. Adding a modality to PAT, or PAT to a modality, does not guarantee response. Response is individualized.

Frequently asked questions

Is PAT ever delivered without a psychotherapy frame? In off-label IV ketamine clinics that do not offer KAP, ketamine is sometimes delivered as a pharmacological intervention alone. This is not psychedelic-assisted therapy as the term is used in the trial literature. Reputable Canadian programs deliver psychedelic medicine inside a defined psychotherapy frame.

Can my existing CBT therapist be part of my psychedelic-assisted therapy? Yes — this is what ATMA CENA's coordinated care model is designed for. Your CBT therapist remains primary; the PAT-specific preparation, dosing, and integration sessions layer on top.

I do EMDR with my therapist for PTSD. Should I switch to MDMA-AT? Switching is not the framing. The clinically coherent question is whether MDMA-AT can be added on top of your existing EMDR work. MDMA-AT in Canada is currently SAP-only; eligibility, access, and coordination with your EMDR therapist are decided clinically.

Is IFS the "best" modality for psychedelic integration? No. IFS is a very strong fit for parts-shaped material that arises during dosing, and is widely used. It is not the only modality, and it is not the right modality for every patient or every indication.

What if my therapist's modality isn't on this list? The list above is not exhaustive. Compassion-Focused Therapy, schema therapy, motivational interviewing, prolonged exposure, narrative therapy, and others can all host PAT work clinically. The relevant question is whether your therapist's frame can hold the material that may arise; coordinated care intake conversations work through this case-by-case.

Is group integration as good as individual integration? Different, not "as good." The Roots to Thrive Dames et al. 2025 Frontiers in Psychiatry paper supports group integration as a clinically reasonable format for selected populations. Some material is better worked one-on-one; the decision is clinical.

Does adding a modality to PAT improve outcomes? The trial literature is combination-only — there is no comparison of "PAT alone" versus "PAT plus modality" because no credible trial has run "PAT alone." The integrity of the combination, and of the patient's primary therapeutic relationship, matters more than which acronym is added.

Can I do PAT with CBCT for couples? Wagner and colleagues' couples-MDMA + CBCT trial work is the leading published example. Access in Canada is currently via SAP and is decided case-by-case. See MDMA-Assisted Therapy in Canada.

Is there a "best" modality for ketamine? No single best modality. CBT, ACT, and IFS are the most-commonly-paired frames in Canadian KAP practice; the right choice depends on indication, patient, and existing care.

What if my therapist is skeptical of psychedelic-assisted therapy? This is common and clinically reasonable. ATMA CENA's coordinated care intake includes the existing therapist explicitly so that scepticism, questions, and clinical concerns can be worked through together rather than around. The patient's primary therapeutic relationship is the asset; the coordinated care model is designed to protect it.

Compliance disclaimer

This article is educational. Psilocybin and MDMA are Schedule III and Schedule I controlled substances in Canada respectively; clinical access in Canada is via Health Canada's Special Access Program on a case-by-case basis. Ketamine is a Health Canada-approved anaesthetic; psychiatric use is off-label and within Canadian off-label prescribing principles. Esketamine (Spravato) is Health Canada-approved for treatment-resistant depression. Nothing in this article should be construed as a clinical recommendation for a specific individual; clinical decisions belong with a qualified prescribing physician.

Sources

1. Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (MAPP1). Nature Medicine, 27(6):1025-1033. PMID: 33972795.
2. Mitchell JM, Ot'alora G M, van der Kolk B, et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (MAPP2). Nature Medicine, 29(10):2473-2480. PMID: 37640273.
3. Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (COMP001). New England Journal of Medicine, 387(18):1637-1648. PMID: 36322843.
4. Schwartz RC. (1995, 2021). Internal Family Systems Therapy (1st and 2nd editions). Guilford Press / Sounds True. Foundational IFS literature.
5. van der Kolk BA. (2014). The Body Keeps the Score: Brain, Mind, and Body in the Healing of Trauma. Viking. Body-based trauma treatment foundation literature; van der Kolk also co-authored MAPP2 (Mitchell 2023).
6. Shapiro F. (2018). Eye Movement Desensitization and Reprocessing (EMDR) Therapy: Basic Principles, Protocols, and Procedures (3rd ed.). Guilford Press.
7. Linehan MM. (1993, 2014). Cognitive-Behavioral Treatment of Borderline Personality Disorder and DBT Skills Training Manual (2nd ed.). Guilford Press. Foundational DBT literature.
8. Hayes SC, Strosahl KD, Wilson KG. (2011). Acceptance and Commitment Therapy: The Process and Practice of Mindful Change (2nd ed.). Guilford Press.
9. Watts R, Luoma JB. (2020). The use of the psychological flexibility model to support psychedelic-assisted therapy. Journal of Contextual Behavioral Science, 15:92-102.
10. Resick PA, Monson CM, Chard KM. (2017). Cognitive Processing Therapy for PTSD: A Comprehensive Manual. Guilford Press.
11. Wagner AC, Mithoefer MC, Mithoefer AT, Monson CM. (2019). Combining Cognitive-Behavioral Conjugal Therapy for PTSD With 3,4-Methylenedioxymethamphetamine (MDMA): A Case Example. Journal of Psychoactive Drugs, 51(2):166-173. PMID: 30967098.
12. Dames S, Kryskow P, Watler C, et al. (2025). Group-based psychedelic-assisted therapy in community mental health: outcomes from the Roots to Thrive program. Frontiers in Psychiatry (Roots to Thrive Nanaimo group integration model).
13. Levine PA. (2010). In an Unspoken Voice: How the Body Releases Trauma and Restores Goodness. North Atlantic Books. Foundational Somatic Experiencing literature.
14. Ogden P, Minton K, Pain C. (2006). Trauma and the Body: A Sensorimotor Approach to Psychotherapy. W. W. Norton. Foundational Sensorimotor Psychotherapy literature.

Related articles

• Preparation Phase of Psychedelic-Assisted Therapy
• Integration Phase of Psychedelic-Assisted Therapy
• Set and Setting in Psychedelic-Assisted Therapy
• Dosing Protocols Across Substances
• Antidepressant Tapering for Psychedelic-Assisted Therapy
• ATMA CENA's coordinated care model — how ATMA CENA layers onto an existing therapeutic relationship
• Group Ketamine Therapy
• Psilocybin Therapy in Canada
• MDMA-Assisted Therapy in Canada
• Ketamine Therapy in Canada

Last updated: 2026-05-06